Dr. Diana Dupont-Roettger hosted a live webinar focused on IO drug development
Please email Eden Chrifi-Alaoui: <eden . chrifi-alaoui @ ia-grp . com> if you wish to listen to the webinar’s recording.
Join Dr. Diana Dupont-Roettger on a live webinar to discuss the role of medical imaging markers and AI in immuno-oncology drug development. The discussion will focus on how non-invasive imaging biomarkers can support our understanding of the underlying biology behind various cancers and predict trial outcomes. The session will begin with Dr. Dupont-Roettger’s talk and will then be followed by an interactive Q&A with the audience.
About the Webinar:
Traditional trial designs and endpoints are no longer suited for the fast-changing clinical Immuno-Oncology (IO) development. The methodologies and design of cancer clinical trials are under profound changes: umbrella, basket, or platform designs, all create a unique opportunity to drive collaboration, coordination, and accelerated innovation. Non-invasive imaging biomarkers can have a unique contribution by helping to understand the underlying biology behind various cancers. Amongst other biomarkers, they create the hope of a more focused and personalized medicine, which has the potential to bring more efficient and tailored treatments to patients.
Key discussion points:
- Understanding Pseudo-Progression through quantification of changes in the tumour microenvironment
- Machine Learning for non-invasive Imaging Phenotyping
- Machine Learning in Digital Pathology
- Predicting immunotherapy response through advanced imaging marker
- IAG’s proprietary cloud technology that supports umbrella, basket, or platform designs to create a unique opportunity to drive collaboration, coordination, and accelerated innovation in the IO field
About Dr. Diana Dupont-Roettger:
Diana is a Medical Computer Scientist by background with strong experience in novel imaging technologies and imaging markers as well as their role for biotech and pharma. She is an expert in scientific imaging clinical trial design and advises biotech and pharma on the strategic use of advanced imaging to evaluate mechanism of action, enable precision medicine and accelerate drug development in immuno-oncology and neuro-oncology indications. Diana is actively working with biotech, pharma and investment funds helping to bridge the gap between academic research, business objectives and finances.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com